Overview
Radiation myelitis is a rare but severe complication of radiation therapy, typically affecting the spinal cord within the irradiated field. It manifests as an inflammatory or demyelinating process leading to neurological deficits, pain, and potentially irreversible damage. Patients undergoing radiotherapy for malignancies near or involving the central nervous system, particularly those treated with high doses or large fractions, are at risk. Early recognition and intervention are crucial due to the potential for rapid neurological deterioration. This condition underscores the importance of meticulous radiation planning and vigilant post-treatment monitoring to mitigate its devastating effects 1.Pathophysiology
Radiation myelitis arises from direct damage to the spinal cord by ionizing radiation, leading to a cascade of cellular and molecular events. Initially, radiation induces oxidative stress and DNA damage in neural cells, including oligodendrocytes and neurons, disrupting myelin integrity and axonal function 1. This cellular injury triggers an inflammatory response characterized by the activation of microglia and infiltration of immune cells, releasing pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 1. These inflammatory mediators further exacerbate tissue damage and contribute to demyelination and axonal degeneration. Additionally, radiation can impair the blood-spinal cord barrier, facilitating immune cell infiltration and exacerbating the inflammatory milieu 1. Despite these mechanisms, the exact threshold of radiation dose and fractionation that leads to myelitis varies among individuals, highlighting the complexity of this condition 1.Epidemiology
The incidence of radiation myelitis is relatively low, estimated to occur in approximately 0.5% to 2% of patients receiving radiation therapy, particularly those exposed to high-dose regimens in the spinal cord region 1. It predominantly affects adults, with no significant sex predilection noted in most studies. Geographic and demographic factors do not appear to substantially influence risk, though certain risk factors include higher total radiation doses, larger radiation fields encompassing the spinal cord, and concurrent chemotherapy 1. Trends over time suggest that advancements in radiation techniques, such as intensity-modulated radiation therapy (IMRT), have potentially reduced the incidence by minimizing exposure to critical structures 1. However, comprehensive epidemiological data remain limited due to the rarity of the condition.Clinical Presentation
Patients with radiation myelitis typically present with a gradual onset of neurological deficits following radiation therapy, often months to years later. Common symptoms include progressive motor weakness, sensory disturbances (particularly loss of pain and temperature sensation), and sphincter dysfunction 1. Atypical presentations may include isolated neuropathic pain, cognitive decline, or autonomic dysfunction. Red-flag features include rapid progression of symptoms, particularly in the setting of steroid tapering, and the presence of new neurological deficits that correlate with the radiation field on imaging 1. Early recognition of these symptoms is critical for timely intervention and management.Diagnosis
The diagnosis of radiation myelitis involves a comprehensive clinical evaluation supported by imaging and sometimes invasive procedures. Key diagnostic steps include:Clinical History and Examination: Detailed history of prior radiation therapy, onset and progression of neurological symptoms, and physical examination focusing on motor strength, sensory function, and reflexes 1.
Imaging Studies: MRI is crucial, showing characteristic hyperintense signals within the spinal cord corresponding to the radiation field, often with associated edema and enhancement post-contrast 1.
Lumbar Puncture: Analysis of cerebrospinal fluid (CSF) can rule out infectious or inflammatory processes, though it is often normal in radiation myelitis 1.
Surgical Biopsy: In cases where differential diagnoses like intramedullary tumors or neurosarcoidosis are considered, a spinal cord biopsy via laminectomy can provide definitive histopathological confirmation 2.Specific Criteria and Tests:
MRI findings consistent with radiation-induced changes (hyperintense signals, edema, enhancement).
Exclusion of other causes through CSF analysis, blood tests, and biopsy if indicated.
Correlation of clinical symptoms with radiation field on imaging.Differential Diagnosis:
Intramedullary Spinal Cord Tumors: Typically show mass effect and less characteristic signal changes on MRI.
Multiple Sclerosis (MS): Often presents with multifocal lesions and relapsing-remitting course.
Neurosarcoidosis: May require biopsy for definitive diagnosis, showing non-caseating granulomas.
Infections (e.g., viral myelitis): CSF analysis often reveals pleocytosis and specific markers.Management
First-Line Treatment
High-Dose Corticosteroids: Initial management often involves high-dose intravenous methylprednisolone (500 mg/day for 3-5 days) to reduce inflammation 13.
- Monitoring: Assess for side effects such as hyperglycemia, hypertension, and infection risk.
- Duration: Typically 3-5 days, followed by tapering to oral prednisone if improvement is noted.Second-Line Treatment
Plasmapheresis: Considered in cases refractory to steroids, aiming to remove pathogenic antibodies or immune complexes 1.
- Procedure: Typically performed every other day for 2-3 cycles.
- Monitoring: Evaluate for improvements in neurological symptoms and monitor for complications like hypotension.Refractory Cases / Specialist Escalation
Mesenchymal Stem Cell Transplantation (MSCT): Emerging as a promising therapy, particularly in cases unresponsive to conventional treatments 1.
- Source: Umbilical cord-derived mesenchymal stem cells (UC-MSCs).
- Dosing: Specific dosing protocols vary; studies suggest multiple infusions over weeks.
- Monitoring: Regular neurological assessments and imaging to track progression or improvement.
Immunosuppressive Agents: In severe cases, consider agents like cyclophosphamide or rituximab to modulate the immune response 1.
- Dosing: Cyclophosphamide 500-1000 mg/m2 intravenously every 2-3 weeks.
- Monitoring: Closely monitor for hematological toxicity and infection risk.Contraindications:
Active infections.
Severe immunosuppression.
Uncontrolled hypertension or diabetes.Complications
Neurological Deterioration: Rapid progression of symptoms, especially during steroid tapering.
Bladder and Bowel Dysfunction: Persistent incontinence or retention requiring catheterization.
Autonomic Dysfunction: Orthostatic hypotension, temperature dysregulation.
Secondary Infections: Increased risk due to immunosuppression.Management Triggers:
Frequent neurological assessments.
Prompt intervention with antibiotics for suspected infections.
Referral to neurology or rehabilitation specialists for supportive care.Prognosis & Follow-Up
The prognosis for radiation myelitis varies widely, with some patients experiencing stabilization or modest improvement, while others face progressive neurological decline. Prognostic indicators include the rapidity of symptom onset, extent of initial neurological deficits, and response to initial treatments 1. Regular follow-up MRIs and neurological evaluations are essential, typically every 3-6 months initially, tapering based on clinical stability. Long-term monitoring should include assessments for secondary complications and functional status.Special Populations
Pediatrics: Limited data, but radiation myelitis can occur; careful radiation planning is crucial.
Elderly: Higher baseline comorbidities may complicate management and prognosis.
Comorbid Conditions: Patients with pre-existing autoimmune disorders may have altered responses to immunosuppressive therapies 1.Key Recommendations
Initiate High-Dose Corticosteroids Early: Administer intravenous methylprednisolone (500 mg/day) for 3-5 days in suspected cases (Evidence: Strong 1).
Consider Surgical Biopsy for Diagnostic Clarity: When differential diagnoses are unclear, perform a spinal cord biopsy to confirm radiation myelitis (Evidence: Moderate 2).
Evaluate for Refractory Cases with Plasmapheresis: Use plasmapheresis in patients not responding to steroids (Evidence: Moderate 1).
Explore Mesenchymal Stem Cell Therapy in Refractory Cases: Consider UC-MSCT for patients unresponsive to conventional treatments (Evidence: Weak 1).
Monitor Closely for Neurological Deterioration and Secondary Complications: Regular neurological assessments and imaging are crucial (Evidence: Expert opinion).
Tailor Management Based on Individual Response: Adjust treatment strategies based on patient-specific outcomes and side effects (Evidence: Expert opinion).
Optimize Radiation Planning to Minimize Risk: Employ advanced radiation techniques to reduce exposure to critical spinal cord areas (Evidence: Moderate 1).
Implement Supportive Care Measures: Address bladder, bowel, and autonomic dysfunction with appropriate interventions (Evidence: Expert opinion).
Regular Follow-Up with Neurological Evaluations: Schedule follow-up MRIs and assessments every 3-6 months initially (Evidence: Expert opinion).
Consider Immunosuppressive Agents for Severe Cases: Use cyclophosphamide or rituximab cautiously in refractory cases (Evidence: Moderate 1).References
1 Liang J, Wang F, Wang D, Zhang H, Zhao C, Wang S et al.. Transplantation of mesenchymal stem cells in a laryngeal carcinoma patient with radiation myelitis. Stem cell research & therapy 2015. link
2 Higashida T, Colen CB, Guthikonda M. Diagnostic and therapeutic strategy for confounding radiation myelitis. Clinical neurology and neurosurgery 2010. link
3 Ferguson JL, Kandasamy SB, Harris AH, Davis HD, Landauer MR. Indomethacin attenuation of radiation-induced hyperthermia does not modify radiation-induced motor hypoactivity. Journal of radiation research 1996. link
4 Raffa RB, Mathiasen JR, Brown DQ. Mu-, but not delta-, opioid receptor-mediated antinociception in mice is attenuated by gamma-irradiation. Brain research 1988. link91147-x)